Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
ADMETox, Alex, Alexander, amplify, antimicrobial, APEXTM, AppliskanTM, assay, Athena, Australian, Bell, BioImage, Bioreactor, Canada, Cardinal, CB, CombiTM, confirmation, conventional, crystalline, DarwinTM, diffraction, DiscoveryTM, DXR, ELISA, entity, enzyme, exciting, FlashTM, FleetTM, FluoroskanTM, formation, GCTM, gene, Georgia, German, GlaxoSmithKline, guidance, HybaidTM, ideal, incubation, infection, irrevocable, Kaufman, kinetic, KingFisherTM, KRILPROTM, likelihood, luminometer, LuminoskanTM, microbial, microscopy, modulate, Multidrop, multimode, MultiskanTM, Mumbai, NanoDrop, Nanogen, NautilusTM, NE, neurological, noncontrolling, nonmonetary, OmniTM, Oryx, pocket, proposed, pump, QPCR, QSPTM, QuantoDesk, quarry, rata, receipt, recipient, renal, robust, SampleManagerTM, scalability, sealing, solid, spectrophotometry, statute, synthetic, tank, therapy, TLP, twelve, UHPLC, unattended, Union, Varioskan, VersaWeigh, VTM, washer, WEEE, winning
Removed:
AB, abuse, AC, advisory, aggregated, auger, beam, Counseling, diffractometry, downturn, epitaxy, expenditure, Graseby, grew, headcount, InnaPhase, intention, liquidate, microspectroscopy, mixture, nearest, noncash, noncurrent, nonoperating, nonqualified, NW, photoelectron, publicly, reclassification, refunded, replaced, restoration, Saturday, simplify, sized, spectra, spinning, spun, subsidiary, ThermoLase, ThermoQuest, VG
Filing tables
Filing exhibits
- 10-K Annual report
- PDF TMO 10-K 2007 (PDF Version)
- 3.3 TMO 10-K 2007 Exhibit 3.3 (Bylaws of the Company)
- 10.70 TMO 10-K Exhibit 10.70 (Executive Change In Control Retention Agreement)
- 10.71 TMO 10-K 2007 Exhibit 10.71 (Fsii Severance Plan for Key Employees)
- 10.72 TMO 10-K 2007 Exhibit 10.72 (Notice of Participation - Alex Stachtiaris)
- 10.73 TMO 10-K 2007 Exhibit 10.73 (Notice of Participation - Alan Malus)
- 10.74 TMO 10-K 2007 Exhibit 10.74 (Letter Agreement with Alan Malus)
- 10.75 TMO 10-K 2007 Exhibit 10.75 (Description of Amendments)
- 10.76 TMO 10-K 2007 Exhibit 10.76 (Amendment to Equity Incentive Plan)
- 10.77 TMO 10-K 2007 Exhibit 10.77 (Amendment to Employees Equity Incentive Plan)
- 10.78 TMO 10-K 2007 Exhibit 10.78 (Amendment to Directors Stock Option Plan)
- 10.79 TMO 10-K 2007 Exhibit 10.79 (Amendment to 2005 Stock Incentive Plan)
- 10.80 TMO 10-K 2007 Exhibit 10.80 (Amendment to 2005 Equity and Incentive Plan)
- 10.81 TMO 10-K 2007 Exhibit 10.81 (Amendment to 2001 Equity Incentive Plan)
- 21 TMO 10-K 2007 Exhibit 21 (Subsidiaries of the Registrant)
- 23.1 Tmmo 10-K 2007 Exhibit 23.1 (PWC Consent)
- 31.1 TMO 10-K 2007 Exhibit 31.1 (Certification)
- 31.2 TMO 10-K 2007 Exhibit 31.2 (Certification)
- 32.1 TMO 10-K 2007 Exhibit 32.1 (Certification)
- 32.2 TMO 10-K 2007 Exhibit 32.2 (Certification)
Related press release
TMO similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marijn E. Dekkers, Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 29, 2008
/s/ Marijn E. Dekkers | |
Marijn E. Dekkers President and Chief Executive Officer |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.